Here, we describe a serological enzyme-linked immunosorbent assay for the screening and
identification of human SARS-CoV-2 seroconverters. This assay does not require the …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global
pandemic with millions infected and more than 1 million fatalities. Questions regarding the …

The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) emerged in the city of
Wuhan, Hubei Province, China, in late 2019. Since then, the virus has spread globally and …

A substantial proportion of influenza-related childhood deaths are due to infection with
influenza B viruses, which co-circulate in the human population as two antigenically distinct …

SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since
infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here…

SARS-CoV-2 mRNA-based vaccines are about 95% effective in preventing COVID-19 1, 2, 3,
4, 5. The dynamics of antibody-secreting plasmablasts and germinal centre B cells …

In late 2019, cases of atypical pneumonia were detected in China. The etiological agent was
quickly identified as a betacoronavirus (named SARS‐CoV‐2), which has since caused a …

Initially, children were thought to be spared from disease caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). However, a month into the epidemic, a novel …

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), is a new human disease with few effective treatments 1 . …

The Ad26.COV2.S vaccine 1 , 2 – 3 has demonstrated clinical efficacy against symptomatic
COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing …